Suggestions
Dimitri van Hoewijk
Partner Corporate / M&A Private Equity and Venture Capital Van Doorne | Life Sciences & Healthcare
Dimitri van Hoewijk is a prominent corporate lawyer and partner at Van Doorne, a law firm based in Amsterdam.15 He specializes in mergers and acquisitions (M&A), with a particular focus on private equity and venture capital transactions.1
Areas of Expertise
Dimitri has extensive experience in the following areas:
- Corporate Law: He is well-versed in handling complex corporate matters.
- Mergers and Acquisitions: Van Hoewijk has years of experience as an M&A lawyer.5
- Private Equity and Venture Capital: He has a strong emphasis on private equity acquisitions.1
- Healthcare and Life Sciences: Dimitri possesses in-depth knowledge of healthcare and life sciences regulations.5
Professional Activities
Van Hoewijk is actively involved in various professional activities:
- He attends international conferences, such as the Annual American Bar Association M&A conference, where he participates in sessions on ESG considerations for private equity investments.6
- Dimitri stays informed about developments in his field, including policy changes related to private equity in healthcare.3
- He shares insights and comments on significant deals in the private equity sector, such as the valuation of Visma, Europe's largest private equity-owned software business.2
Thought Leadership
Dimitri van Hoewijk is recognized as an influential figure in the Dutch legal landscape:
- He has been listed among the Top 10 Influential Dutch Healthcare Lawyers.7
- Van Hoewijk shares his thoughts on broader societal changes, noting that "We are not living in an era of change, but in a change of era," referencing shifts in politics, climate, and technology.4
Through his work at Van Doorne and his active presence on professional platforms like LinkedIn, Dimitri van Hoewijk demonstrates his expertise and thought leadership in corporate law, M&A, and the healthcare sector.
Highlights
#privateequity #investereninzorg #winstuitkering
Dutch healthcare minister reiterates intention to research role private equity in healthcare In answer to parliamentary questions, outgoing Dutch healthcare Minister Kuipers has reiterated his intention to do conduct further research into the role of private equity in Dutch healthcare. Although the parliamentary questions solely focus on the suggested locust role of private equity investors - which is suggested to inherently result in a decrease of the quality of care once a financial sponsor has invested in the healthcare provider - Minister Kuipers emphasis that private equity investors can play an important and positive role in amongst others increasing innovation in the Dutch healthcare sector. Also Minister Kuipers refers to his earlier comments that existing regulations in respect of the quality of care and (current and proposed) legislation in respect of the (im)possibilities for healthcare providers to pay out dividends will of course also fully apply to healthcare providers with a private equity owner and there is no need for specific other regulations. Currently, the Dutch Healthcare Inspectorate (IGJ) and the Dutch Healthcare Authority (NZa) are conducting an investigation into a general practitioners platform and its buy & build strategy. In answer to further parliamentary questions in respect of this investigation, Minister Kuipers confirmed his consideration to authorize the NZa to in (temporarily) prohibit acquisitions by a healthcare provider who is subject to an IGJ and/or NZa investigation. Although instigated by said general practitioners platform, such authority would not specifically be aimed at private equity owned healthcare providers. These parliamentary questions reflect the critical position of certain political parties in respect of private equity investors in Dutch healthcare sector and on the one hand the need by the healthcare Minister to respond to these parties but on the other hand the much more nuanced position of Cabinet itself which inherently results in increasingly growing and complicated regulations for privately held healthcare providers.
